Qualigen Therapeutics Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Kevin Richardson

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	2.3yrs

Son yönetim güncellemeleri

Recent updates

Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M

Aug 16

Qualigen Therapeutics files mixed shelf offering of up to $150M

Jul 29

Qualigen partners Hande Sciences to support its application enabling studies for QN-302

Jul 06

Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?

Mar 08

We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate

Nov 23

CEO

Kevin Richardson (56 yo)

less than a year

Görev süresi

Mr. Kevin A. Richardson, II, is Interim CEO, Interim CFO & Director of Qualigen Therapeutics, Inc. from September 26, 2024 and serves as its Chairman since 2024. Mr. Richardson served as the Chairman at SA...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Poirier	Chief Operating Officer	no data	US$632.70k	0.057% $ 1.6k
Kevin Richardson	Interim CEO	less than a year	Veri yok	Veri yok
Robert W. Becher	President & Director	less than a year	Veri yok	Veri yok
Christopher Lotz	VP of Finance & Corporate Secretary	1.9yrs	US$3.02m	0.0034% $ 97.4

0.3yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: QLGN 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kevin Richardson	Interim CEO	less than a year	Veri yok	Veri yok
Robert W. Becher	President & Director	less than a year	Veri yok	Veri yok
Michael Gordon	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Anthony Tolcher	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Lillian Siu	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Robert Lim	Independent Director	less than a year	Veri yok	Veri yok
Wayne Klohs	Chair of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Patricia LoRusso	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Christopher Slapak	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Braeden Lichti	Independent Director	less than a year	Veri yok	Veri yok
Stephen Neidle	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Cody Price	Independent Director	less than a year	Veri yok	Veri yok

2.3yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: QLGN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/22 17:33
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Qualigen Therapeutics, Inc. 2 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
James Molloy	Alliance Global Partners
David Bautz	Zacks Small-Cap Research

Qualigen Therapeutics Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Qualigen Therapeutics, Inc. Announces Board and Committee Changes

Qualigen Therapeutics, Inc. Announces Chief Financial Officer Changes

Less than half of directors are independent

Qualigen Therapeutics, Inc., Annual General Meeting, Sep 17, 2024

Qualigen Therapeutics, Inc. Announces Board Changes

Qualigen Therapeutics, Inc. Announces Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and Director

Recent updates

Qualigen Therapeutics, Inc. announced that it has received $5.1 million in funding

Qualigen Therapeutics, Inc. announced that it expects to receive $4.5 million in funding

Qualigen Therapeutics to Implement a 1-for-50 Reverse Stock Split, to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Qualigen Therapeutics, Inc. has filed a Follow-on Equity Offering.

Qualigen Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Audit Committee

Qualigen Therapeutics, Inc. Announces Board and Committee Changes

Qualigen Therapeutics, Inc. Announces Chief Financial Officer Changes

New major risk - Financial data availability

Qualigen Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3.458613 million.

Less than half of directors are independent

The Nasdaq Hearings Panel Grants Qualigen Therapeutics Until October 31, 2024 to Regain Compliance with the Bid Price Rule and the Equity Rule

Qualigen Therapeutics, Inc., Annual General Meeting, Sep 17, 2024

Qualigen Therapeutics, Inc. Announces Board Changes

Qualigen Therapeutics Receives Nasdaq Notice of a Delisting Determination Due to its Continued Non-Compliance with the Minimum Bid Price Requirement, Pursuant to Listing Rule 5550(b)(2)

Qualigen Therapeutics, Inc. announced delayed 10-Q filing

Qualigen Therapeutics, Inc. announced delayed annual 10-K filing

Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital Anstalt

Consensus revenue estimates decrease by 14%, EPS upgraded

Qualigen Therapeutics Receives a Letter from the Nasdaq Stock Market

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Consensus EPS estimates fall by 57%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Qualigen Therapeutics Announces UD FDA IND Clearance to Initiate Phase 1 Clinical Trial of Qn-302 for Treatment of Advanced or Metastatic Solid Tumors

Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. (NasdaqCM:QLGN).

Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. (NasdaqCM:QLGN).

New minor risk - Share price stability

Qualigen Therapeutics, Inc. Announces Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and Director

Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Qualigen Therapeutics, Inc., Annual General Meeting, Jul 13, 2023

Qualigen Therapeutics, Inc. Announces the Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and A Director, Effective June 16, 2023

Price target decreased by 23% to US$27.00

Consensus revenue estimates decrease by 12%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Qualigen Therapeutics, Inc. Initiates Good Laboratory Practice Toxicology Studies on QN-302

Qualigen Therapeutics, Inc. Announces Executive Changes

Qualigen Therapeutics, Inc. announced that it expects to receive $3.3 million in funding

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Qualigen Therapeutics, Inc. Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

Consensus forecasts updated

High number of new and inexperienced directors

Qualigen Therapeutics, Inc., Annual General Meeting, Oct 28, 2022

Nasdaq Grants Qualigen Therapeutics 180-Day Extension to February 27, 2023 to Regain Compliance with the Minimum Bid Price Requirement

High number of new and inexperienced directors

Consensus forecasts updated

Consensus revenue estimates increase by 10%

Qualigen Therapeutics, Inc. Announces Formation and First Meeting of QN-302 Scientific Advisory Board

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M

Qualigen Therapeutics, Inc. Reports Positive Qn-247 Readout in Triple Negative Breast Cancer in Vivo Model

Qualigen Therapeutics files mixed shelf offering of up to $150M

Qualigen partners Hande Sciences to support its application enabling studies for QN-302

Price target decreased to US$5.75

Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials

Qualigen Therapeutics, Inc. (NasdaqCM:QLGN) completed the acquisition of a 53% stake in NanoSynex Ltd. from shareholder.

Qualigen Therapeutics, Inc. (NasdaqCM:QLGN) entered into definitive agreement to acquire an unknown majority stake in NanoSynex Ltd. from shareholder.

Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?

We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate

Price target decreased to US$8.25

Second quarter 2021 earnings released: US$0.18 loss per share (vs US$2.12 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.13 loss per share (vs US$0.16 loss in 1Q 2020)

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri